Advances in insulin: a review of icodec as a novel once-weekly treatment for type 2 diabetes
Javier Morales,Aaron King,Sean Oser,Sherwin D’Souza
DOI: https://doi.org/10.1080/00325481.2024.2410694
2024-10-08
Postgraduate Medicine
Abstract:Type 2 diabetes (T2D) is a chronic condition that requires not only a team-based approach but also substantial self-management by those affected. Patient-clinician barriers such as lack of educational resources, hesitancy in initiation of therapy, concerns over treatment-related side effects, frequency of dosing, and the establishment of treatment goals, can prevent a patient from achieving optimal glycemic management. Recently, advances in diabetes technology and insulin formulations have helped to address some of these concerns. Insulin icodec, the first once-weekly basal insulin analog, has demonstrated efficacy and safety comparable to traditional basal insulin formulations. Since clinicians and patients may benefit from a once-weekly therapy, this review sought to evaluate the potential clinical implications of insulin icodec. A literature search was performed using PubMed, Google Scholar, and ClinicalTrials.gov up to 31 January 2024. Key search terms such as once-weekly basal insulin, icodec, and ONWARDS were utilized to compile relevant publications. Further, studies involving patients living with T2D on once-weekly insulin icodec compared with once-daily basal insulin were considered for this review. Findings from this review suggest insulin icodec can offer a reduced dosing frequency that may improve medication adherence, provide effective glycemic management, and a comparable safety profile to existing basal insulins. In summary, insulin icodec may help to remove patient-clinician barriers associated with suboptimal glycemic management with its once-weekly dosing schedule. Clinicians can further support a patient's ability to self-manage the disease through continued monitoring and guidance on the use of icodec. Type 2 diabetes can be a challenging illness to manage since patients and clinicians often encounter obstacles such as limited access to educational resources, concerns about starting treatment, worries about side effects, and inconvenient dosing schedules. While recent advancements in diabetes technology and insulin formulations have helped, there's still a need for more information to ease concerns about treatment. Insulin icodec, an insulin taken just once a week, has shown to be just as effective and safe as traditional daily insulins. Since both clinicians and patients may benefit from the use of a once-weekly therapy, we evaluated the possible impact of insulin icodec on clinical practice and patient outcomes. To do this, researchers collected and read scientific articles published online on or before 31 January 2024. Key search terms were used during the online search. After a review of the articles, the authors found that insulin icodec could not only simplify treatment by reducing the number of injections needed but also control blood sugar as effectively as existing insulin options. In summary, insulin icodec has the potential to address many of the challenges associated with managing type 2 diabetes, offering a simpler dosing schedule that could improve adherence and overall blood sugar. Continued support and guidance from clinicians and interdisciplinary team members can further enhance a patient's ability to manage their diabetes effectively with insulin icodec.
medicine, general & internal